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Each year approximately two million
hospitalizations result in nosocomial infections
(1). In a study of critically ill patients in a large
teaching hospital, illness attributable to nosoco-
mial bacteremia increased intensive care unit
stay by 8 days, hospital stay by 14 days, and the
death rate by 35% (2). An earlier study found
that postoperative wound infections increased
hospital stay an average of 7.4 days (3).
Staphylococcus aureus was the most com-
mon cause of nosocomial infections reported in
the National Nosocomial Surveillance System
between 1990 to 1996 (4). The leading cause of
nosocomial pneumonia and surgical site infec-
tions and the second leading cause of nosocomial
bloodstream infections (4), S. aureus also causes
community-acquired infections (e.g., osteomyeli-
tis and septic arthritis, skin infections,
endocarditis, and meningitis). More than 95% of
patients with S. aureus infections worldwide do
not respond to first-line antibiotics such as
penicillin or ampicillin (5). Additionally, methi-
cillin-resistant strains of S. aureus (MRSA) are
common. First reported in the 1960s (6), MRSA
has become increasingly prevalent since the
1980s (7,8) and is now endemic in many hospitals
and even epidemic in some, with resistance in
approximately 30% of all S.aureus infections (8).
Vancomycin is the only drug that can
consistently treat MRSA. However, beginning in
1989, hospitals have reported a rapid increase in
vancomycin resistance in enterococci (VRE) (9).
Increased vancomycin use helps select for VRE,
and even a small increase in incidence of VRE
infection could lead to cross-resistance in
S. aureus, since genes conferring vancomycin
resistance might be transferred from VRE (10).
In 1996, Japan reported the first case of S.
aureus infection with intermediate resistance to
vancomycin (11). In 1997, two unrelated cases
of S. aureus infection with intermediate
resistance to vancomycin were reported in the
United States (Michigan and New Jersey) (12).
In both cases, patients had been treated with
multiple courses of vancomycin for repeated
MRSA infections over the 6 months before the S.
aureus infection with intermediate resistance to
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We modeled estimates of the incidence, deaths, and direct medical costs of
Staphylococcus aureus infections in hospitalized patients in the New York City
metropolitan area in 1995 by using hospital discharge data collected by the New York
State Department of Health and standard sources for the costs of health care. We also
examined the relative impact of methicillin-resistant versus -sensitive strains of S.
aureus and of community-acquired versus nosocomial infections. S. aureus-associated
hospitalizations resulted in approximately twice the length of stay, deaths, and medical
costs of typical hospitalizations; methicillin-resistant and -sensitive infections had
similar direct medical costs, but resistant infections caused more deaths (21% versus
8%). Community-acquired and nosocomial infections had similar death rates, but
community-acquired infections appeared to have increased direct medical costs per
patient ($35,300 versus $28,800). The results of our study indicate that reducing the
incidence of methicillin-resistant and -sensitive nosocomial infections would reduce the
societal costs of S. aureus infection.
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vancomycin; additionally, VRE colonization had
been diagnosed 7 months before the S. aureus
infection with intermediate resistance to vancomy-
cin in the New Jersey patient. The emergence of
S. aureus infection with intermediate resistance
to vancomycin in the United States suggests that
S. aureus strains are constantly evolving and full
resistance may develop (12).
The various ways of controlling MRSA (13)
are still being debated. The elimination of
endemic MRSA in hospitals is difficult and costly
(14-17). In general, infection control in the
United States is less stringent than in Canada
and in some European countries, where
identification of known carriers, prospective
surveillance of patients and hospital workers,
and use of nasal mupirocin have helped control
drug-resistant S. aureus infection rates (18).
Knowledge of the scope of the problem is
helpful for hospital administrators, insurers, and
medical personnel who make policy decisions on
control measures to prevent the spread of MRSA
and the emergence of vancomycin-resistant S.
aureus. However, the economic cost of S. aureus
infections is not well known. Many studies focus
on the cost of nonorganism-specific nosocomial
infections (2,19,20). Moreover, the reported cost
of a nosocomial infection varies because of the
wide range of study populations, sites of
infection, and methods used (16,21). The few
investigations into the cost of S. aureus
infections have focused on the differential cost of
MRSA and MSSA infections (22,23) and are case
studies of outbreaks in single hospitals. Thus,
they do not provide perspective on the scope of
the problem for a population over time.
We estimated the incidence, death rate, and
cost of S. aureus infections associated with
hospitalization in the New York City metropoli-
tan area in 1995. We selected this geographic
region because of its high prevalence of
multidrug-resistant infections (24,25). We also
compared the relative contributions of nosoco-
mial versus community-acquired infections and
methicillin-sensitive (MSSA) versus methicillin-
resistant S. aureus.
The Study
Data
The 1995 Statewide Planning and Research
Cooperative System (SPARCS) Administratively
Releasable File was the primary source of data
(26). SPARCS is a database of all hospital
discharges in New York state, as reported by
hospitals to the State of New York Department of
Health, and the Administratively Releasable
File contains discharge information on hospital
location, patient characteristics (age, sex, race,
ethnicity), and visit characteristics (primary
diagnosis, secondary diagnoses, primary proce-
dure, secondary procedures, length of stay, total
charges, patient status, and disposition). We
analyzed data for hospitals in the following New
York City metropolitan area counties: Bronx,
Dutchess, Kings, Manhattan, Nassau, Orange,
Putnam, Queens, Richmond, Rockland, Suffolk,
Ulster, and Westchester. Data on infection
incidence or resource use not in SPARCS were
obtained through a comprehensive literature
search or estimated by a clinical panel consisting
of four physicians specializing in infectious
disease. Other sources for cost information were
the 1995 Medicare Fee Schedule (27) for physician
fees and the 1995 Red Book (28) for outpatient
pharmaceutical average wholesale prices.
Definitions
We identified patients with the most
common types of hospital-associated S. aureus
infections: pneumonia, bacteremia, endocarditis,
surgical site infections, osteomyelitis, and septic
arthritis (Table 1) from SPARCS, which uses the
International Classification of Diseases, Ninth
Revision, Clinical Modification (ICD-9-CM)
diagnosis codes (29). With the exception of ICD-
9-CM code 482.4 (staphylococcal pneumonia)
and 038.1 (staphylococcal septicemia), these
codes are not organism-specific.
To identify S. aureus infections, we used the
nonorganismspecific codes in conjunction with
an additional ICD-9-CM code to identify the
bacterial agent (i.e., 041.11 bacterial infection
due to S. aureus in conditions classified
elsewhere and of unspecified site). Patients with
multiple infections were counted only once in the
overall incidence rate. Their primary or first
occurrence of a diagnosis of interest was used.
Because source of infection (nosocomial
versus community-acquired) is not reported in
SPARCS, we assumed that specific types of
disease were either nosocomial or community-
acquired on the basis of the clinical panel
opinion (Table 2).
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Modeling the Incidence Rate
ICD-9-CM code 041.11 (bacterial infection
due to S. aureus) is not widely used by reporting
hospitals. Therefore, the incidence of S. aureus
infections based on the counts of 041.11 in SPARCS
would underestimate the number of cases. We
estimated the incidence of S. aureus infections
(except pneumonia) as follows (Table 3): the total
incidence of each type of infection (e.g.,
endocarditis) in SPARCS was multiplied by the
Table 1. ICD-9-CM codes used to identify infections in Statewide Planning and Research Cooperative System
Type of Infection ICD-9-CMa Description
Pneumonia 482.4 Pneumonia due to staphylococcus
Bacteremia 038.1 Staphylococcal septicemia
790.7 Bacteremia
996.62 Infection and inflammatory reaction due to internal
      vascular device, implant, and graft
Endocarditis 421.0 Acute and subacute bacterial endocarditis
996.61 Infection and inflammatory reaction due to cardiac device,
       implant, and graft
Surgical site infection 998.3 Disruption of operation wound
998.5 Postoperative infection
Osteomyelitis 730.01-730.09 Acute osteomyelitis
730.10-730.19 Chronic osteomyelitis
Septic arthritis 711.00-711.09 Pyogenic arthritis
996.66 Infection and inflammatory reaction due to internal joint
       problems
aInternational classification of diseases, 9th Revision, Clinical Modification, 1995.
Table 2. Definitions of nosocomial or community-acquired Staphylococcus aureus infections
Type of Infection Nosocomial Community-acquired
Pneumonia Secondary diagnosisa Primary diagnosisa
Bacteremia Catheter- or surgery- Noncatheter- and nonsurgical-
     associated infectionsb      associated infections
Endocarditis Prosthetic valve infections Natural valve infections
Surgical site infection (SSI) All SSIs None
Osteomyelitis None All
Septic arthritis Prosthetic joint infections Natural joint infections
aICD-9-CM 482.4 as the primary diagnosis vs. 482.4 as one of several other diagnoses.
bICD-9-CM 996.62, or 038.1 associated with a surgical ICD procedure code, or 790.7 associated with a surgical ICD procedure
code.
Table 3. Incidence of Staphylococcus aureus infections from research or clinical panel
Type of S. aureus
infection Description % Reference
Bacteremia Staphylococcal septicemia 50          30
Bacteremia 15        31,32
Infection and inflammatory reaction due to internal 16            4
      vascular device, implant, and graft
Endocarditis Acute and subacute bacterial endocarditis 30 Clinical panel
Infection and inflammatory reaction due to 14          33
      cardiac device, implant, and graft
Surgical site Disruption of operation wound and postoperative 20           4
  infection        infection
Osteomyelitis Acute and chronic osteomyelitis 50      34,35
Septic arthritis Pyogenic arthritis 11 (age <5 yr)         33
33 (age 5-18 yr)
55 (age >18 yr)
Infection and inflammatory reaction due to 25         33
       internal joint prosthesis
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estimated percentage attributable to S. aureus
(determined by research or clinical panel
opinion) to give the total number of infections
due to S. aureus. The incidence of pneumonia
was equated with the occurrence of the ICD-9-
CM code 482.4 (staphylococcal pneumonia). For
ICD-9-CM code 038.1 (staphylococcal septice-
mia), we assumed that only 50% of infections
were attributable to S. aureus (with the
remainder attributable to S. epidermidis) (30).
Modeling Death Rates
The death rates attributable to bacteremia,
endocarditis, or community-acquired pneumo-
nia were assumed to be equal to the death rates
found when these infections were coded as a
primary diagnosis in SPARCS and 041.11 was
used as a secondary diagnosis. For nosocomial
pneumonia, however, we assumed that the
attributable death rate was a percentage of the
actual death ratefor ventilator-associated
pneumonia patients, death rate is a function of
both the severity of underlying disease and the
pneumonia. A series of matched-cohort studies
have demonstrated that the death rate
attributable to ventilator-associated pneumonia
is 0% to 57% of the actual death rate (36-39). On
the basis of this research and expert panel
judgment, nosocomial pneumonia in ventilator-
associated pneumonia patients (identified by
ICD-9-CM V46.0 or V46.1) was assumed to have
an attributable death rate of 50% of the death rate
found in SPARCS (30,40). We assumed that the
attributable death rate of nonventilator-associ-
ated pneumonia was the death rate found in
SPARCS. On the basis of the low death rate found
in SPARCS (approximately 2%), we assumed that
no deaths were attributable to osteomyelitis,
septic arthritis, or surgical site infections.
Modeling Direct Medical Costs
Direct medical costs were defined as hospital
costs attributable to S.aureus infection, profes-
sional fees incurred during hospitalization, and
costs of other infection-related medical services
provided after discharge. For each infection,
total direct medical costs were calculated by
multiplying the average direct medical cost per
patient by the incidence of disease. Average
hospital costs attributable to S. aureus per
patient were assumed to be equal to the average
hospital charge from SPARCS when the
infection (e.g., pneumonia, bacteremia) was
coded as a primary diagnosis and 041.11 was
used as a secondary diagnosis. Professional fees
incurred during hospitalization include physi-
cian visits and consultations for evaluation and
management, as well as radiologic, surgical, and
anesthesiologic costs. The average frequency of
physician services per patient was based on
clinical panel estimates. Costs of these services
were based on 1995 Medicare Payment Rates for
the Long Island, New York, area as an
intermediate point between New York City costs
and those of outlying counties.
Costs of medical services after discharge
include those of postdischarge complications (e.g.,
abscesses, aneurysms) requiring rehospitalization,
home-based intravenous antibiotic therapy, and
outpatient oral antibiotic therapy. The average
frequency of other medical services provided per
patient was based on clinical panel estimates.
Costs of hospital readmission were based on
SPARCS charges; costs of home-based intrave-
nous therapy were based on literature estimates
(40,41); and costs of outpatient medications were
based on average wholesale prices (25).
Modeling MRSA and MSSA S. aureus
Infections
SPARCS does not identify MRSA or MSSA
infections, and a code for infection with a drug-
resistant organism (V09) is rarely used.
Therefore, we modeled the comparative inci-
dence, death rate, and cost of MRSA and MSSA.
We computed the incidence of MRSA and MSSA
infections by using the estimate that 29% of
infections were due to MRSA (8). The clinical
panel estimated that 10% of community-
acquired infections were due to MRSA (includes
infections acquired at long-term care facilities).
The number of deaths for MRSA and MSSA
infections was estimated as follows: the clinical
panel estimated a risk ratio for death rates of
MRSA and MSSA infections, and deaths due to
MRSA and MSSA infections were calculated from
the estimated risk ratio and the overall number
of deaths due to S. aureus infection. We estimated
the direct medical cost per patient for MRSA and
MSSA infections as follows: differences in resource
use for those with MRSA and MSSA infections
were identified by the clinical panel; these
differences were converted into differences in cost
using a method similar to that described above
for modeling direct medical costs; and average
costs for MRSA and MSSA infections were
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calculated by using the average cost for an
S. aureus infection and the average difference in
cost between MRSA and MSSA infections.
Incidence, Death Rate, and Attributable
Costs
S. aureus Infection
Of 1,351,362 nonobstetrical hospital dis-
charges in SPARCS for New York City in 1995,
an estimated 13,550 (1.0%) were discharges of
patients with S. aureus infections (Table 4). The
total direct medical costs incurred by these
patients was an estimated $435.5 million
average length of stay nearly 20 days, direct cost
of infection, $32,100 (Table 4). The number of
deaths was estimated at 1,400 (a 10% death rate).
In contrast, the hospital charges for the average
hospital stay in SPARCS (for all nonobstetrical
discharges) were $13,263average length of
stay 9 days, death rate 4.1%. Thus, patients with
S. aureus infection had approximately twice the
cost, length of stay, and death rate of a typical
hospitalized patient.
Pneumonia and bacteremia represented
most S. aureus infections and accounted for 60%
of the total direct medical costs and 97% of the
number of deaths. Endocarditis caused the
longest stay (26 days) and highest direct cost per
patient ($47,200); surgical site infection caused
the shortest stay (14 days) and lowest direct
cost per patient ($21,810). Hospital charges
were an average of $29,000 (90% of the total
costs); professional fees were an average of
$2,300 (7%); and postdischarge costs repre-
sented $800 (3%) (Table 5).
Nosocomial Infection
Nosocomial infections accounted for 46% of
the total incidence of S. aureus infections (6,300
infections), while community-acquired infec-
tions accounted for 54% (7,250 infections) (Table
6). Community-acquired pneumonia as a
primary diagnosis accounted for 12% (1,500) of
the total cases. If community-acquired pneumo-
nia is assumed to be mostly acquired in long-
term care facilities, most infections (58%) were
acquired institutionally. The cost attributable to
community-acquired infections ($35,300) was
approximately $6,500 higher on a per patient
basis than the cost attributable to nosocomial
infections ($28,800). The death rates attribut-
able to community-acquired and nosocomial
infections were similar (10.5% and 10.1%).
Table 4. Incidence, length of stay, costs, and death rates of Staphylococcus aureus infections by type of infection
Direct Medical Cost
Length of stay Total Per patient Deaths
Type of infection Incidence (days) ($M) ($) Total %
Pneumonia   3,600 22.2 128.3 35,400    890 25
Bacteremia   4,400 18.0 137.0 31,300    470 11
Endocarditis      550 25.9   25.8 47,200      40   7
Surgical site infection   2,300 13.6   50.5 21,800     NDa ND
Osteomyelitis   2,000 23.9   68.4 35,000     ND ND
Septic arthritis      700 22.0   25.5 35,100     ND ND
Total or average 13,550 19.8 435.5 32,100 1,400 10
aND=no data.
Table 5. Direct medical charges—average hospital
facility charges, professional fees, and postdischarge
costs per case
Profes- Post-
Hospital sional discharge
Type of charges  fees  costs Total
infection $      (%) $    (%) $    (%) $
Pneumonia 33,400 (94) 2,000 (6)      NDa 35,400
Bacteremia 27,900 (89) 2,100 (7) 1,300 (4) 31,300
Endo- 41,700 (88) 4,300 (9) 1,200 (3) 47,200
  carditis
Surgical 20,200 (93) 1,600 (7)      ND 21,800
  site
  infection
Osteo- 30,000 (86) 3,200 (9) 1,800 (5) 35,000
  myelitis
Septic 30,600 (87) 3,100 (9) 1,400 (4) 35,100
  arthritis
Average 29,000 (90) 2,300 (7)    800 (3) 32,100
aND=no data.
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MRSA Infection
MRSA infections accounted for 21% (2,780)
of the total S. aureus infection incidence (29% of
6,300 nosocomial infections plus 10% of 7,250
community-acquired infections), while MSSA
infections accounted for 79% (10,770) of total
infections (Table  6). The attributable cost of a
patient with MRSA was approximately $2,500
higher than the attributable cost of a patient
with MSSA ($34,000 versus $31,500). The higher
cost of MRSA infections is due to the higher cost
of vancomycin, longer hospital stay, and the cost
of patient isolation procedures. For nosocomial
infections alone, the cost attributable to MRSA
was approximately $3,700 higher on a per
patient basis than the cost attributable to MSSA
infections ($31,400 versus $27,700). The death
rate attributable to MRSA infections was
estimated at more than 2.5 times higher than that
attributable to MSSA infections (21% versus 8%).
Sensitivity Analyses
Although assumed to be underused in
SPARCS, the ICD-9-CM code 041.11 represents
a lower boundary of the total incidence of S.
aureus infection. In SPARCS, code 041.11 was
used 7,366 times associated with a diagnosis of
interest (e.g., endocarditis) and represented a
total cost of $236.4 million and a death rate (740
deaths) of 2% (Table 7). The upper boundary of
the total cost of S. aureus infections was
calculated by assuming that all hospital charges
and deaths of patients with S. aureus infections
were attributable to the infection, representing a
total cost of $599 million and a death rate of
14.5% (1,960 deaths). We conducted sensitivity
analyses (varying the percentage of nosocomial
MRSA; percentage of patients isolated; differ-
ence in length of stay between patients with
MRSA and MSSA; attributable length of stay for
patients with ventilator-associated pneumonia;
number of S. aureus catheter infections; and
percentage of S. aureuscaused bacteremia,
septicemia, and postoperative infections) and
found that the difference in cost per case between
MRSA and MSSA infections was $1,700 to $5,100.
Comments
Our sensitivity analysis shows that we did
not vastly over- or underestimate the direct
medical costs of S. aureus infections in New York
City. However, the study had several limitations;
it was retrospective, and the data sources were
not validated by other means (e.g., interviews or
chart review). Therefore, coding errors in this
database may affect the results. The clinical
panel estimates we used to model differences
between MRSA and MSSA may lead to some
inaccuracy in those difference estimates. Thus,
our comparison of costs and deaths between
MRSA and MSSA should be viewed as a best
approximation in the absence of case-control
data or a multivariate analysis of a well-defined
patient population.
Our estimates of the cost per infection are
generally higher than estimates in studies
reviewed by Jarvis (19). A major reason may be
our focus on New York City, where costs are
much higher than in other areas of the United
States. In addition, earlier studies have used
only hospital costs. Our perspective was societal;
therefore, we included physician fees and
outpatient costs, as well as hospital charges.
Finally, most of these studies focused on non
organism-specific nosocomial infections; S. aureus
infections may have a higher average cost per
Table 6. Incidence, length of stay, costs, and deaths of
Staphylococcus aureus infections by source of infection
and degree of resistance
Direct medical cost
Per
Source of Total patient Deaths
infection Incidence ($M) ($) Total (%)
Nosocomial   6,300 181.0 28,800 640 10
Community   7,250 254.5   5,300 760 11
  Pneumonia   1,500   51.7 34,900 380 25
  Non-   5,750 202.8 35,400 380   7
   pneumonia
MRSAa   2,780   94.5 34,000 590 21
MSSAb 10,770 339.4 31,500 810   8
aMethicillin-resistant strains of S. aureus.
bMethicillin-sensitive strains of S. aureus.
Table 7. Sensitivity analyses
Direct
medical cost
($) Deaths
Study results 435.5 1,400
Lower boundary: 236.4    740
  only 041.11 cases
Upper boundary:
  all costs attributable 599.0 1,960
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episode than infections of other organisms (42).
On the other hand, we used conservative
estimates for certain costs. Medicare prices for
professional services are generally lower than
commercial rates. Also, we did not account for
postdischarge complications that did not lead to
hospitalization. Additionally, our societal esti-
mates did not include the cost of dying or lost
productivity associated with these illnesses.
Despite its limitations, this study shows that
hospitalizations associated with S. aureus are
serious and have high medical costs and death
rates. The average length of stay attributable to
S. aureus infection for these patients was very
high, 20 daysnearly three times the average
for any other type of hospitalization (43). The
increased length of stay in turn leads to increases
in direct medical costs, with an average cost per
case of $32,100 in 1995.
Treating an MRSA infection costs 6% to 10%
more than treating an MSSA infection ($2,500 to
$3,700 per case). This cost difference does not
reflect MRSAs greater virulence; rather, it
reflects the increased cost of vancomycin use and
isolation procedures (if used). These estimates
are slightly lower than the difference of $5,104
found by Wakefield et al. (21), perhaps because
they focused on the cost of serious S. aureus
infections, while our analysis examined all
hospitalizable S. aureus infections.
Patients with MRSA infections have a high
average attributable death rate of 21% versus 8%
for an MSSA infection. Some of the death rate
difference may be related to the underlying
condition of patients who become infected with
MRSA (e.g., older patients, drug users, sicker
patients, patients previously exposed to other
antibiotics) (44) and to the lack of effectiveness of
vancomycin itself in curing MRSA. (Vancomycin
has a narrow therapeutic index that allows little
room for increasing blood concentration without
incurring substantial losses in tolerance [45]).
Both MSSA and MRSA infections are
associated with high costs and large numbers of
deaths in the New York City metropolitan area.
The costs and deaths associated with S. aureus
infections may dramatically increase if the newly
isolated S. aureus infection with intermediate
resistance to vancomycin spreads or if VRSA
emerges. For example, after penicillin-resistant
S. aureus appeared in the 1950s, the death rate
of bacteremia increased from 28% to 50% at the
University of Minnesota (Figure) (46). After
methicillin was introduced, the death rate
decreased (47). Efforts should be directed toward
reducing the incidence of MRSA and MSSA
nosocomial infections to reduce their economic
impact on society.
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